Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNot Yet Recruiting
NCT07776509Phase 3Updated Aug 20, 2026
Sponsor: AstraZeneca
Obesity or Overweight · Weight-Related Comorbidity · With/Without Diabetes Mellitus, Type 2
United States, Argentina, Brazil, Canada, China +6 more
Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07170917Phase 2Updated Aug 20, 2026
Sponsor: Sanofi
Hidradenitis Suppurativa
United States, Australia, Canada, Chile, China +14 more
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT04910568Phase 1Updated Aug 20, 2026
Sponsor: Genentech, Inc.
Multiple Myeloma
United States, Australia, Canada, Czechia, Denmark +8 more
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruiting
NCT07129993Phase 2, Phase 3Updated Aug 20, 2026
Sponsor: Daiichi Sankyo
Urothelial Cancer · Bladder Cancer
United States, Austria, China, France, Germany +2 more
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive Not Recruiting
NCT05976243Phase 3Updated Aug 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Inducible Urticaria
United States, Argentina, Australia, Brazil, Canada +23 more
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Active Not Recruiting
NCT05649748Phase 2, Phase 3Updated Aug 20, 2026
Sponsor: Insmed Incorporated
Pulmonary Arterial Hypertension
United States, Argentina, Austria, Belgium, Brazil +10 more
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06819878Phase 3Updated Aug 20, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
United States, Argentina, Australia, Austria, Belgium +33 more
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisCompleted
NCT06921759Phase 3Updated Aug 20, 2026
Sponsor: Eli Lilly and Company
Atopic Hand and Foot Dermatitis
United States, Argentina, Australia, Canada, Japan +3 more
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEActive Not Recruiting
NCT06957080Phase 2, Phase 3Updated Aug 20, 2026
Sponsor: EyeBiotech Ltd.
Diabetic Macular Edema (DME)
United States, Argentina, Brazil, Colombia, Japan +1 more
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19Completed
NCT05305547Phase 3Updated Aug 20, 2026
Sponsor: Shionogi
SARS-CoV-2 Infection
United States, Argentina, Brazil, Colombia, Ghana +12 more
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisRecruiting
NCT06470048Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Diffuse Cutaneous Systemic Sclerosis
United States, Argentina, Austria, Belgium, Brazil +20 more
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruiting
NCT06467357Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Austria, Belgium, Brazil +22 more
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruiting
NCT05714839Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: GlaxoSmithKline
Multiple Myeloma
United States, Argentina, Australia, Brazil, China +8 more
A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the BloodSuspended
NCT07656792Phase 1Updated Aug 19, 2026
Sponsor: Boehringer Ingelheim
Healthy
Japan
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsRecruiting
NCT07241039Phase 1Updated Aug 19, 2026
Sponsor: AbbVie
Advanced Squamous Tumors
United States, Canada, Israel, Japan
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruiting
NCT07492641Phase 3Updated Aug 19, 2026
Sponsor: BeOne Medicines
HR+/HER2- Breast Cancer
United States, Australia, Brazil, China, Japan +5 more
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruiting
NCT07181109Phase 3Updated Aug 19, 2026
Sponsor: Alnylam Pharmaceuticals
High Risk Cardiovascular Disease · Hypertension · High Cardiovascular Risk
United States, Argentina, Australia, Austria, Belgium +29 more
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaRecruiting
NCT06556563Phase 3Updated Aug 19, 2026
Sponsor: NovoCure GmbH
Glioblastoma
United States, Canada, Czechia, France, Germany +7 more
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerRecruiting
NCT07617337Phase 1Updated Aug 19, 2026
Sponsor: Chugai Pharmaceutical
ALK Positive Non-small Cell Lung Cancer
Japan
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Recruiting
NCT06937229Phase 3Updated Aug 19, 2026
Sponsor: Bristol-Myers Squibb
Alzheimer Disease · Agitation
United States, Argentina, Brazil, Bulgaria, Canada +21 more
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Recruiting
NCT06767514Phase 3Updated Aug 19, 2026
Sponsor: Summit Therapeutics
Non-Small Cell Lung Cancer
United States, Belgium, Canada, China, France +12 more
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoRecruiting
NCT07431177Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Non-segmental Vitiligo
United States, Argentina, Australia, Canada, China +7 more
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNot Yet Recruiting
NCT07668336Phase 3Updated Aug 19, 2026
Sponsor: Eli Lilly and Company
Diabetes Mellitus, Type 2
United States, Belgium, Brazil, India, Italy +6 more
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive Not Recruiting
NCT04958239Phase 1Updated Aug 19, 2026
Sponsor: Boehringer Ingelheim
Neoplasms
United States, Australia, Belgium, Brazil, China +10 more
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive Not Recruiting
NCT05100862Phase 3Updated Aug 19, 2026
Sponsor: BeOne Medicines
Relapsed/Refractory Follicular Lymphoma · Marginal Zone Lymphoma
United States, Argentina, Australia, Austria, Belgium +23 more

Previous page Next page